Licenses U.S. rights to fosfomycin trometamol, a single-dose antibiotic for uncomplicated urinary tract infections, from Italian firm Zambon Group. Forest will copromote and codevelop the product, which is delivered as a 3 gram sachet that is reconstituted with water. The agreement "is the first in a network of U.S. partnerships planned" by Zambon, the company said Nov. 20. Two-arm Phase III trials that are designed to enroll 600 evaluable patients total are "well-advanced" in the U.S., Forest says, with an NDA filing "planned by the end of 1992" under Zambon's name. Fosfomycin is marketed in eight countries as Monuril.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth